Аналитики прогнозируют рост акций 20/20 Biolabs на 788% по сравнению с конкурентами

20/20 Biolabs (NASDAQ:AIDX – Get Free Report) is one of 237 public companies in the “Healthcare Providers & Services” industry, but how does it weigh in compared to its competitors? We will compare 20/20 Biolabs to similar businesses based on the strength of its valuation, institutional ownership, profitability, dividends, risk, analyst recommendations and earnings. Analyst Recommendations This is a summary of current ratings and target prices for 20/20 Biolabs and its competitors, as provided by MarketBeat.com. 20/20 Biolabs currently has a consensus target price of $5.00, indicating a potential upside of 788.10%. As a group, “Healthcare Providers & Services” companies have a potential upside of 11.82%. Given 20/20 Biolabs’ higher possible upside, equities research analysts plainly believe 20/20 Biolabs is more favorable than its competitors. Valuation & Earnings 20/20 Biolabs’ competitors have higher revenue and earnings than 20/20 Biolabs. 20/20 Biolabs is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry. Profitability This table compares 20/20 Biolabs and its competitors’ net margins, return on equity and return on assets. Institutional & Insider Ownership 57.2% of shares of all “Healthcare Providers & Services” companies are held by institutional investors. 29.8% of 20/20 Biolabs shares are held by insiders. Comparatively, 15.4% of shares of all “Healthcare Providers & Services” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Summary 20/20 Biolabs competitors beat 20/20 Biolabs on 7 of the 12 factors compared. About 20/20 Biolabs We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026. Both tests are run in our CAP (College of American Pathologists) accredited, CLIA (Clinical Laboratory Improvement Amendments) licensed laboratory in Gaithersburg, MD. That laboratory also hosts our Clinical Laboratory Innovation Accelerator, or CLIAx, which we believe is the country’s first shared CLIA laboratory for overseas diagnostics start-ups seeking to launch novel lab tests in the U.S. without the expense of establishing and operating their own, independent lab. As noted above, during the COVID-19 pandemic, we also provided COVID-19 viral testing using polymerase chain reaction, or PCR, analytical equipment in our clinical laboratory. Our legacy business also includes a pioneering field test kit for screening suspicious powders for bioterror agents known as BioCheck. As of the date of this prospectus, we generate revenue from three sources: OneTest for Cancer (primarily as a lab test in the U.S. but we also license our algorithms to overseas labs), BioCheck and from our CLIAx. For each of the nine months ended September 30, 2025 and 2024, sales of OneTest for Cancer accounted for approximately 87% of our revenues, sales of BioCheck accounted for approximately 9% of our revenues, and our CLIAx accounted for approximately 4% of our revenues. For the years ended December 31, 2024 and 2023, sales of OneTest for Cancer accounted for approximately 85% and 65% of our revenues, respectively, sales of BioCheck accounted for approximately 10% and 13% of our revenues, respectively, our CLIAx accounted for approximately 5% and 4% of our revenues, respectively, and COVID-19 testing accounted for approximately 0% and 18% of our revenues, respectively. Our principal executive offices are located in Gaithersburg, MD. Receive News & Ratings for 20/20 Biolabs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for 20/20 Biolabs and related companies with MarketBeat.com's FREE daily email newsletter.